Alteration of striatal glutamate release after glutamine synthetase inhibition

J Neurochem. 1984 Nov;43(5):1438-46. doi: 10.1111/j.1471-4159.1984.tb05406.x.


The effect of the glutamine synthetase (GS) inhibitor, methionine sulfoximine (MSO), on glutamate levels in, and glutamate release from, rat striatal tissue was examined. Tissue levels of glutamate were unchanged 24 h after an intraventricular injection of MSO, but tissue glutamine levels were decreased 50%. Calcium-dependent, potassium-stimulated glutamate release was diminished in tissue prisms from animals pretreated with MSO compared to controls. The decreased release of glutamate correlated over time with the inhibition of GS following an intraventricular injection of MSO. The maximum diminution of calcium-dependent, potassium-stimulated glutamate release (50%) and the maximum inhibition of GS activity (51%) were observed 24 h after MSO. The addition of 0.5 mM glutamine to the perfusion medium completely reversed the effects of MSO pretreatment on calcium-dependent, potassium-stimulated glutamate release. Since GS is localized in glial cells and the measured glutamate release is presumed to occur from neurons, the data support the contention that astroglial glutamine synthesis is an important contributor to normal neuronal neurotransmitter release.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Calcium / pharmacology
  • Corpus Striatum / metabolism*
  • Glutamate-Ammonia Ligase / antagonists & inhibitors*
  • Glutamates / metabolism*
  • Glutamic Acid
  • Kinetics
  • Male
  • Methionine Sulfoximine / pharmacology*
  • Potassium / pharmacology
  • Rats
  • Rats, Inbred Strains


  • Glutamates
  • Methionine Sulfoximine
  • Glutamic Acid
  • Glutamate-Ammonia Ligase
  • Potassium
  • Calcium